



December 02, 2025

To, Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Ref: BSE Scrip Code: 544497	To, The National Stock Exchange of India Ltd. The Listing Department Exchange Plaza, Bandra – Kurla Complex, Mumbai – 400051, NSE Scrip Code: AHCL
--	---

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).

Dear Sir/Madam,

With reference to the captioned subject, we would like to inform you that the Company has entered into a Share Purchase Agreement (SPA) dated December 2, 2025 with Apiqo Organics Private Limited (*formerly known as M/s Apple Life Science, a partnership firm*) (“Target Company”) for acquisition of 67.48% shareholding of the Target Company from 3 shareholders of such Target Company, in accordance with and subject to the terms and conditions as set out in the SPA.

Pursuant to the terms of the SPA and upon fulfilment of the conditions precedent contained in the SPA, Purchaser being the Company will acquire management and control of the Target Company, and upon completion of such acquisition, the Target Company will become Subsidiary of the Company.

The Annexure contains details pursuant to Schedule III of the Listing Regulations and additional details as required under the SEBI Master Circular for compliance with the provisions of the Listing Regulations by listed entities, bearing ref. SEBI/HO/CFD/PoD2/CIR/P/0155, dated November 11, 2024.

You are requested to take the above information on your record.

Thanking You.

For ANLON HEALTHCARE LIMITED

**PUNITKUMAR RASADIA
MANAGING DIRECTOR
DIN: 06696258**

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



ANNEXURE-A

Details required under Regulation 30 of SEBI LODR read with SEBI Circular
SEBI/HO/CFD/PoD2/CIR/P/0155, dated November 11, 2024

Sr No.	Particulars	Description
1	Name of the target entity, details in brief such as size, turnover etc.;	<p><u>Name:</u> Apiqo Organics Private Limited (<i>formerly Known as M/s Apple Life Science, a partnership firm</i>) ("Target Company") (CIN: U21001GJ2025PTC169863) is an Indian private limited company, incorporated on December 1, 2025, by way of conversion from the partnership firm to a private limited company.</p> <p><u>Brief details:</u> The Target Company is <i>inter alia</i> engaged in manufacturing pharmaceutical intermediate, industrial and fine chemicals and inorganic chemicals,</p> <p><u>Turnover:</u> Rs.977.78/- Lakh (as on 31.03.2025) and Rs.3,887.41/- Lakh (as on 31.10.2025)</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No
3	Industry to which the entity being acquired belongs;	Pharmaceuticals
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	<p>The proposed strategic acquisition of the Target Company significantly enhances the Company's vertical integration, secures critical supply of high-quality intermediates, increases additional 700 to 800 MT annual manufacturing capacity for advanced pharmaceutical intermediates, and strengthens the ability of the Company to deliver reliable, cost-effective solutions to our global pharmaceutical partners.</p> <p>The proposed acquisition not only secures supply of critical materials for the Company but also positions it as a more agile, cost-competitive,</p>

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in



		and reliable partner for innovator and generic pharmaceutical companies worldwide.								
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable								
6	Indicative time period for completion of the acquisition;	The proposed acquisition is subject to completion of certain customary closing conditions under the SPA and is expected to be completed within 3 months from the date of signing of the SPA or by such other timelines as may be mutually agreed between the parties								
7	Consideration - whether cash consideration or share swap or any other form and details of the same;	The consideration would be paid in cash.								
8	Cost of acquisition and/or the price at which the shares are acquired;	<u>Cost of acquisition:</u> Rs.5,40,06,960/- <u>Price at which shares are acquired:</u> 55,33,500 equity shares at price of Rs.9.76/- each aggregating Rs.5,40,06,960/-.								
9	Percentage of shareholding / control acquired and / or number of shares acquired;	<u>Percentage of shareholding acquired:</u> 67.48% of the Target Company <u>Control acquired:</u> Yes <u>Number of shares acquired:</u> 55,33,500 equity shares of the Target Company.								
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<u>Brief background:</u> Please refer (1) above. <u>Country in which the acquired entity has presence:</u> India <u>Turnover for the last 3 years:</u> <table><tr><td>Financial Year</td><td>Amt. in Lakh</td></tr><tr><td>2022-23</td><td>Rs. 982.34</td></tr><tr><td>2023-24</td><td>Rs. 1,711.10</td></tr><tr><td>2024-25</td><td>Rs. 977.78</td></tr></table>	Financial Year	Amt. in Lakh	2022-23	Rs. 982.34	2023-24	Rs. 1,711.10	2024-25	Rs. 977.78
Financial Year	Amt. in Lakh									
2022-23	Rs. 982.34									
2023-24	Rs. 1,711.10									
2024-25	Rs. 977.78									

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in